Hip implant manufacturers in the UK appeal NICE (National Institute for Clinical Excellence) ruling
This article was originally published in Clinica
Hip implant manufacturers in the UK have launched an appeal against draft recommendations on the clinical and cost effectiveness of their products by the National Institute for Clinical Excellence (NICE).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.